消化道肿瘤免疫相关不良事件的临床分析

首都医科大学学报 ›› 2023, Vol. 44 ›› Issue (2): 343-350.doi: 10.3969/j.issn.1006-7795.2023.02.024

• 临床研究 • 上一篇下一篇

消化道肿瘤免疫相关不良事件的临床分析

孙婧^#，史幼梧^#，杜丰，杨颖，孙志伟，余靖，肖艳洁，张晓东，贾军^*

北京大学肿瘤医院暨北京市肿瘤防治研究所VIP-II病区，恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142

收稿日期:2022-11-29 出版日期:2023-04-21 发布日期:2023-04-18
通讯作者: 贾军 E-mail:vm26@netease.com

Clinical analysis of immune-related adverse events in gastrointestinal cancer

Sun Jing^#, Shi Youwu^#, Du Feng, Yang Ying, Sun Zhiwei, Yu Jing, Xiao Yanjie, Zhang Xiaodong, Jia Jun^*

VIP-II Gastrointestinal Cancer Division of the Department of Medicine, Peking University Cancer Hospital & Institute； Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing 100142, China

Received:2022-11-29 Online:2023-04-21 Published:2023-04-18

摘要/Abstract

摘要： 目的探讨消化系统恶性肿瘤中免疫检查点抑制剂(immune checkpoint inhibitors, ICIs）导致免疫相关不良事件(immune-related adverse events, irAEs)的特征及危险因素。方法回顾性分析2019年4月至2021年10月北京大学肿瘤医院诊治的95例接受ICIs治疗的消化系统恶性肿瘤患者的临床资料和irAEs发生情况。irAEs、内分泌irAEs危险因素分析采用二元Logistic回归分析。结果 95例患者共应用ICIs治疗458例次，中位应用3例次(范围：1~33例次）。irAEs的发生率为55.8%，3~4级irAEs发生率为9.5%。最常见的irAEs为皮肤irAEs(27.4%）和内分泌irAEs(22.1%）。内分泌irAEs中甲状腺功能减退最常见(16.8%），肾上腺皮质功能减退(2.1%）和垂体炎(1.1%）少见。多数irAEs发生于免疫治疗初期，78.2%发生于12周内。过敏反应、皮肤irAEs最早发生，中位发生时间分别为2周(范围：0.9～3.1周）和3.8周(范围：0.9～17.9周），内分泌irAEs中位发生时间为6.9周(范围：3.0～52.1周）。多因素分析显示，女性(OR=5.197, 95%CI：1.166～23.154, P=0.031)和微卫星高度不稳定(microsatellite instability-high，MSI-H） (OR=35.048, 95%CI：2.756～445.787, P=0.006)是内分泌irAEs发生风险增加的独立危险因素，免疫治疗联合化学药物治疗(OR=0.107, 95%CI：0.021～0.412, P=0.001）是内分泌irAEs的独立保护性因素。结论在消化系统恶性肿瘤中应用ICIs具有较好的安全性。女性和MSI-H患者出现内分泌irAEs风险增加，联合化学药物治疗可能降低内分泌irAEs发生风险。

关键词: 消化系统恶性肿瘤, 免疫检查点抑制剂, 免疫相关不良事件

Abstract: Objective To identify the characteristics and risk factors associated with immune-related adverse events (irAEs) in gastrointestinal cancer patients treated with immune checkpoint inhibitors (ICIs). Methods We retrospectively investigated clinical data of 95 gastrointestinal cancer patients from April 2019 to October 2021 in Peking University Cancer Hospital. The clinical characteristics and irAEs data of these patients were analyzed. Binary Logistic regression analysis was used to identify irAEs and endocrine irAEs risk factors. Results In the 95 patients enrolled, the total number and median number of ICIs treatment cycles were 458 and 3(range:1-33). The incidence of irAEs and grade 3-4 irAEs were 55.8% and 9.5%, respectively. The most common irAEs were skin irAEs (27.4%) and endocrine irAEs (22.1%). Among endocrine irAEs, hypothyroidism occurred most frequently (16.8%), while adrenocortical dysfunction (2.1%) and hypophysitis (1.1%) were rare. Most irAEs occurred in the early stage of immunotherapy, and 78.2% occurred within 12 weeks. The earlier onset irAEs were allergy and skin irAEs, with a median occurrence time of 2 weeks (range:0.9－3.1 weeks) and 3.8 weeks (range:0.9－17.9 weeks), respectively. The median onset time of endocrine irAEs was 6.9 weeks (range:3.0－52.1 weeks). Multivariate analysis revealed that female(OR=5.197,95%CI：1.166－23.154,P=0.031） and microsatellite instability-high (MSI-H）(OR=35.048, 95%CI：2.756－445.787, P=0.006）were independent risk factors of endocrine irAEs. Immunotherapy combined with chemotherapy (OR=0.107, 95%CI：0.021－0.412, P=0.001） was an independent protective factors. Conclusion The application of ICIs in patients with gastrointestinal cancer was well tolerated. Female and MSI-H patients have an increased risk of endocrine irAEs. Immunotherapy combined with chemotherapy may reduce the risk of endocrine irAEs.

Key words: gastrointestinal cancer, immune checkpoint inhibitors, immune-related adverse events

中图分类号:

R730
R735

孙婧, 史幼梧, 杜丰, 杨颖, 孙志伟, 余靖, 肖艳洁, 张晓东, 贾军. 消化道肿瘤免疫相关不良事件的临床分析[J]. 首都医科大学学报, 2023, 44(2): 343-350.

Sun Jing, Shi Youwu, Du Feng, Yang Ying, Sun Zhiwei, Yu Jing, Xiao Yanjie, Zhang Xiaodong, Jia Jun. Clinical analysis of immune-related adverse events in gastrointestinal cancer[J]. Journal of Capital Medical University, 2023, 44(2): 343-350.

参考文献

［1］Arnold M, Abnet C C, Neale R E, et al. Global burden of 5 major types of gastrointestinal cancer［Ｊ］. Gastroenterology, 2020, 159(1):335-349.e15.
［2］Vrána D, Matzenauer M, Neoral C∨, et al. From tumor immunology to immunotherapy in gastric and esophageal cancer［Ｊ］. Int J Mol Sci, 2018, 20(1):13.
［3］Hsu A, Mendelson L, Almhanna K. Immune checkpoint inhibitors in the treatment of gastrointestinal malignancies: a review of current and future therapies［Ｊ］. R I Med J (2013), 2020, 103(3):33-37.
［4］Suazo-Zepeda E, Bokern M, Vinke P C, et al. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis［Ｊ］. Cancer Immunol Immunother, 2021, 70(11):3069-3080.
［5］Fujisawa Y, Yoshino K, Otsuka A, et al. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab［Ｊ］. J Dermatol Sci, 2017, 88(2):225-231.
［6］Cappelli L C, Dorak M T, Bettinotti M P, et al. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis［Ｊ］. Rheumatology (Oxford), 2019, 58(3):476-480.
［7］Tarhini A A, Zahoor H, Lin Y, et al. Baseline circulating IL-１7 predicts toxicity while TGF-β1 and IL-１0 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma［Ｊ］. J Immunother Cancer, 2015, 3: 39.
［8］Ghosh N, Chan K K, Jivanelli B, et al. Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review［Ｊ］. J Clin Rheumatol, 2022, 28(2):e498-e505.
［9］Von Itzstein M S, Khan S, Gerber D E. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis［Ｊ］. Clin Chem, 2020, 66(6):779-793.
［10］National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5.0［EB/OL］. (2021-04－１9)［2021-11-29］. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.
［11］Brahmer J R, Abu-Sbeih H, Ascierto P A, et al. Society forImmunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events［Ｊ］. J Immunother Cancer, 2021, 9(6):e002435.
［12］Haanen J B A G, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up［Ｊ］. Ann Oncol, 2017, 28(Suppl 4):iv119-iv142.
［13］中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南: 2021［M］. 北京: 人民卫生出版社, 2021: 1－１66.
［14］Postow M A, Sidlow R, Hellmann M D. Immune-related adverse events associated with immune checkpoint blockade［Ｊ］. N Engl J Med, 2018, 378(2):158－１68.
［15］Khoja L, Day D, Chen T W W, et al. Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review［Ｊ］. Ann Oncol, 2017, 28(10):2377-2385.
［16］Das S, Ciombor K K, Haraldsdottir S, et al. Immune-related adverse events and immune checkpoint inhibitor efficacy in patients with gastrointestinal cancer with food and drug administration-approved indications for immunotherapy［Ｊ］. Oncologist, 2020, 25(8):669-679.
［17］Arnaud-Coffin P, Maillet D, Gan H K, et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors［Ｊ］. Int J Cancer, 2019, 145(3):639-648.
［18］Eigentler T K, Hassel J C, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-１ antibody therapy［Ｊ］. Cancer Treat Rev, 2016, 45: 7－１8.
［19］Wang D Y, Salem J E, Cohen J V, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis［Ｊ］. JAMA Oncol, 2018, 4(12):1721－１728.
［20］Byun D J, Wolchok J D, Rosenberg L M, et al. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies［Ｊ］. Nat Rev Endocrinol, 2017, 13(4):195-207.
［21］Girotra M, Hansen A, Farooki A, et al. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management［Ｊ］. JNCI Cancer Spectr, 2018, 2(3):pky021.
［22］Valpione S, Pasquali S, Campana L G, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade［Ｊ］. J Transl Med, 2018, 16(1):94.
［23］Muir C A, Clifton-Bligh R J, Long G V, et al. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment［Ｊ］. J Clin Endocrinol Metab, 2021, 106(9):e3704-e3713.
［24］Postow M A, Sidlow R, Hellmann M D. Immune-related adverse events associated with immune checkpoint blockade［Ｊ］. N Engl J Med, 2018, 378(2):158－１68.
［25］Maekura T, Naito M, Tahara M, et al. Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer［Ｊ］. In Vivo, 2017, 31(5):1035－１039.
［26］Kimbara S, Fujiwara Y, Iwama S, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab［Ｊ］. Cancer Sci, 2018, 109(11):3583-3590.
［27］Cortellini A, Buti S, Santini D, et al. Clinical outcomes of patients with advanced cancer andpre-existing autoimmune diseases treated with anti-programmed death-１ immunotherapy: a Real-World transverse study［Ｊ］. Oncologist, 2019, 24(6):e327-e337.
［28］Saxena P, Singh P K, Malik P S, et al. Correction to: immunotherapy alone or in combination with chemotherapy as first-line treatment of non-small cell lung cancer［Ｊ］. Curr Treat Options Oncol, 2020, 21(11):91.
［29］Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab pluschemotherapy for squamous non-small-cell lung cancer［Ｊ］. N Engl J Med, 2018, 379(21):2040-2051.
［30］Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab pluschemotherapy in metastatic non-small-cell lung cancer［Ｊ］. N Engl J Med, 2018, 378(22):2078-2092.
［31］Reck M, Rodríguez-Abreu D, Robinson A G, et al. Pembrolizumab versuschemotherapy for PD-L1-positive non-small-cell lung cancer［Ｊ］. N Engl J Med, 2016, 375(19):1823－１833.
［32］Mok T S K, Wu Y L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042):a randomised, open-label, controlled, phase 3 trial［Ｊ］. Lancet, 2019, 393(10183):1819－１830.

相关文章 1

编辑推荐

Metrics

本文评价